NCT02706691View on ClinicalTrials.gov

BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

June 1, 2018

Primary Completion Date

February 11, 2019

Study Completion Date

February 11, 2019

Conditions
FGFR Gene AmplificationFGFR1 Gene AmplificationFGFR2 Gene AmplificationFGFR2 Gene MutationFGFR3 Gene MutationHead and Neck Squamous Cell CarcinomaHuman Papillomavirus InfectionRecurrent Head and Neck CarcinomaRecurrent Nasopharynx CarcinomaRecurrent Oropharyngeal Squamous Cell Carcinoma
Interventions
DRUG

BGJ398

Given by mouth (oral)

Trial Locations (1)

60637

University of Chicago Comprehensive Cancer Center, Chicago

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

University of Chicago

OTHER